Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xentuzumab + Enzalutamide in mCRPC
NCT02204072Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2014
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, randomised, open-label trial of xentuzumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicities, Maximum Tolerated Dose and 2 more. Started Nov 2014; status: completed.
02
Drugs
xentuzumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02204072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204072.